Journal
OBESITY SURGERY
Volume 30, Issue 4, Pages 1605-1610Publisher
SPRINGER
DOI: 10.1007/s11695-019-04248-x
Keywords
Gastric bypass; Hypoglycemia; Hyperglycemia; Pasireotide; Somatostatin analogs
Categories
Ask authors/readers for more resources
Post-bariatric hypoglycemia (PBH) can be a serious complication after Roux-en-Y gastric bypass (RYGB), and treatment with somatostatin analogs has been suggested. We investigated the acute effects of three different doses of pasireotide (75 mu g, 150 mu g, and 300 mu g) on the postprandial glucose metabolism in five RYGB-operated individuals with PBH using a mixed meal test. All three doses prevented hypoglycemia but were associated with a notable increase in postprandial hyperglycemia. Moreover, all doses greatly diminished insulin, C-peptide, and glucagon-like peptide-1 responses. Considering its strong hyperglycemic potential, we suggest that pasireotide should be administered carefully in RYGB-operated individuals with PBH, and if necessary, a 75 mu g dose seems sufficient to prevent hypoglycemia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available